Search all ALPCO products, resources, and website information

About Us
About Magento Store Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Morbi luctus. Duis lobortis. Nulla nec velit. Mauris pulvinar erat non massa. Suspendisse tortor turpis, porta nec, tempus vitae, iaculis semper, pede. Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Mo...
Tips & Tricks
The Enzyme-Linked Immunosorbent Assay (ELISA) is a proven sensitive method for detecting and quantifying specific biomarkers in a wide range of clinical and research samples. The accuracy and precision of ELISAs can be affected by many factors, including pipetting, washing, and sample-handling techn...
Responsibility
ALPCO’s Diabetes Research Travel GrantALPCO strives to provide scientists and healthcare professionals with robust tools for their research and clinical diagnostic endeavors. We understand that championing extraordinary discoveries requires extraordinary efforts, and support. We are proud to continu...
Life Science Research
Moving your life science research toward breakthroughs with reagents and walk-away, sample-to-answer solutionsWhether you’re doing basic or translational life science research, you need ready access to the platforms, assays, products, and other tools that are essential to your work. ALPCO has been d...
ALPCO's New FDA Cleared 25-OH Vitamin D Total ELISA Provides Option for Hospitals and Smaller Clinical Labs to Bring Affordable Testing In-House
ALPCO announced in a press release on January 22, 2014 that their test portfolio for clinical and hospital laboratory customers has expanded to include a new FDA 510(k) cleared 25-OH Vitamin D Total ELISA. The growth in 25-OH Vitamin D testing has been a challenge for clinical and hospital labora...
ALPCO Releases New Chemiluminescent Human C-peptide ELISA
ALPCO announced the launch of its new STELLUX® Chemiluminescent Human C-peptide ELISA on December 5, 2014. This highly characterized assay measures C-peptide requiring only 50 µL of human serum, plasma or cell culture supernatant. The ELISA exhibits greater sensitivity and a broader dynamic range co...
Complement System Solutions for Drug Development and Clinical Research
Datasheet: Complement System Immunoassays Download The complement system is essential to innate immunity which protects from chronic, autoimmune, and infectious disease. There are three distinct pathways of complement activation: classical, lectin/MBL, and alternative. Each leads...
Bone Metabolism: The Cycle of Bone Growth and Resorption
Bone metabolism is a continual cycle of bone growth and resorption that is carefully orchestrated by the dynamic relationship between osteoclasts, osteoblasts and an array of hormonal and regulatory influences. The relative levels of these signaling molecules dictate whether healthy, balanced bo...
Toxicology
Drug-Induced Organ Injury Toxicological side effects are a common obstacle in drug development pipelines and often manifest in site-specific damage to vital organs, including the liver, kidney and heart. Estimates of compound attrition from failure to meet safety endpoints are as high as 45% in pre...
How Should We Define Vitamin D Deficiency?
Date: July 21, 2015 Author: Bethany Bell, PhD; Senior Product Manager at ALPCO Dr. Anders Berg presented at the Northeast Laboratory Conference in October 2014 regarding a much debated topic: vitamin D deficiency and how this should be defined. Dr. Berg referenced over one thousand studies, re...
Understanding the Role of Energy Homeostasis in Diabetes
Introduction The prevalence of diabetes and obesity has been on the rise for several decades and research has demonstrated that other parts of the body, including the cardiovascular system and kidneys, can be affected by diabetes. The key to understanding the relationship between diabetes and the...
ALPCO and Cisbio US, Inc. Announce Sales and Distribution Agreement
Date: July 1, 2015 ALPCO is pleased to announce a strategic account sales and distribution agreement with Cisbio US, Inc. Cisbio will now have exclusive access to ALPCO’s high quality STELLUX® Chemiluminescence and colorimetric Diabetes and Obesity assay portfolio in order to provide these produc...
De-escalating Inflammatory Bowel Disease Therapies
Date: June 21, 2016 Author: Andrea Tarbet, Product Marketing Associate at ALPCO Several therapies exist to help treat inflammatory bowel disease (IBD) and improve patient quality of life. However, a growing number of gastroenterologists and patients have been choosing to stop these therapies -...
BTK Inhibitors as Cancer Drug Treatments
Date: July 26, 2016 Author: Andrea Tarbet, Product Marketing Associate at ALPCO Over the past several years, the drug arsenal to combat B cell cancers has gained a mighty weapon: Bruton’s tyrosine kinase (BTK) inhibitors. The origins of using BTK inhibitors as cancer drug treatments actually b...
Class IA PI3K Inhibitor Cancer Therapies
Date: August 16, 2016 Author: Andrea Tarbet, Product Marketing Associate at ALPCO Bruton’s tyrosine kinase (BTK) inhibitors are not the only kinase inhibitors to enter the fight against B cell cancers. Since there are numerous subtypes of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), p...
PI3K Delta Signaling in Rheumatoid Arthritis
Date: September 6, 2016 Author: Andrea Tarbet, Product Marketing Associate at ALPCO Signaling pathways dictate the differentiation, activation, and functions of immune cells.  Even the slightest problem in one cell signaling pathway can transform the immune system and turn it against the body,...
Regulating Endocrine Disrupting Chemicals in Consumer Products
Date: September 27, 2016 Author: Andrea Tarbet, Product Marketing Associate at ALPCO From cosmetics to water bottles, endocrine disrupting chemicals (EDCs) have surfaced in our everyday lives. EDCs are compounds that can interfere with the endocrine system’s ability to help an organism develop...
ALPCO and InSphero Collaborate to Advance Metabolic Disease Research at ADA 2017
Date: June 6, 2017 ALPCO announced it will collaborate with InSphero, a supplier of 3D cell culture solutions, at the ADA’s 77th Scientific Sessions June 10-12 in San Diego. Together, ALPCO and InSphero aim to enhance the study of islet function, regeneration, and preservation by providing resear...
Dorothy Hodgkin’s Discovery of Insulin's 3D Structure
Nobel Prize winning British chemist Dr. Dorothy Hodgkin significantly contributed to unraveling the secrets of diabetes mellitus. She is considered a founder of X-ray crystallography, a technique used to discern the structures of organic biomolecules. Dorothy Hodgkin’s discovery of insulin's 3D...
Investigating Immunogenicity of IBD Biologics
Biologics have been commonly prescribed as therapies for inflammatory bowel disease (IBD) since the late 1990s. However, research demonstrates that not all individuals respond to the first biologic taken and many lose response over time1. As a result, there is a great need to explore the immunogenic...
ALPCO and InSphero Partner to Offer a Complete Solution to Assess Beta-cell Function in Islet Microtissue Culture Models
July 23, 2018 ALPCO recently announced its partnership with InSphero, AG to provide customers with a complete solution to assess beta-cell function in islet microtissue culture models. InSphero’s 3D InSight™ Diabetes Discovery Platform offers users a comprehensive beta-cell function applic...
An Accurate Solution to the Challenges with Measuring GLP-1
Glucagon-like peptide-1 (GLP-1) is a gut hormone which plays an essential role in insulin secretion and glucose homeostasis1. While GLP-1 has become central to many metabolic disease research programs, various GLP-1 ELISA kits currently available on the market have been failing to meet the needs of ...
ALPCO’s Quality Management System Receives ISO 13485:2016 Certification
October 8, 2018 ALPCO recently announced that its quality management system received the distinguished ISO 13485:2016 certification from Intertek. ALPCO’s certification applies to the design, development, manufacture, and distribution of in vitro diagnostic reagents and kits. The Internati...
ALPCO Announces Inaugural Young Investigators Award Recipient
October 17, 2018 ALPCO has announced the first recipient of its new young investigators award, the Diabetes Research Travel Grant. The grant was created to help advance progressive diabetes and obesity research by graduate students, postdoctoral fellows, and early stage investigators. The program...